CCME Global Limited announces allotment of shares for acquisitions and preferential issues
CCME Global · Pharmaceuticals & Biotechnology
Key highlights
- On October 28, 2026, CCME Global allotted 15.08 crore equity shares worth ₹150.84 crore, including 1.8 crore shares for cash to three non-promoters.
- Acquired 45% of Cash & Carry Middle East FZCO (CCME UAE) by issuing 11.25 crore shares valued at ₹112.5 crore; CCME UAE turnover was AED 6.9 crore and net profit AED 44 lakh for period ending June 30, 2026.
- Acquired 52% of Interlink Distribution LLC by issuing 2.03 crore shares valued at ₹20.34 crore; Interlink turnover was AED 70 lakh and net profit AED 5.4 lakh for period ending June 30, 2026; Interlink now a subsidiary from October 28, 2026.
Why it's rated major development: the amount is 98% of market value (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Allotment
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from CCME Global
- Fundraise / allotmentMajor developmentCCME Global allots 15,08,42,244 shares; Interlink a subsidiary, CCME UAE an associate
Other fundraise / allotment filings this fortnight
- Clean Max Enviro: Q2 results, NCDs up to Rs 3,000 crore approved, IFSC subsidiary planned
- Lloyds Metals and Energy Limited approves Q2 results, investment, and fundraising plans
- Lloyds Metals approves Q2 results, ₹625 crore TEIL investment and USD 300 million debt
- Mena Mani Industries approves Sept 2026 results, hotel venture and software expansion
- Sat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
- CL Educate Limited approves ₹140 Cr fund raise and reports Q2 FY27 financials
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.